Chen Z, et al. - Via meta-analysis, the value of bevacizumab in combination with chemotherapy and single-agent therapy in recurrent glioblastoma treatment was determined. Analysis of 1,169 patient cases from seven randomized controlled trials revealed that significantly improved progression-free survival and objective response rate could be achieved with bevacizumab combined with chemotherapy, but with no prolongation of overall survival. The combination therapy may also lead to higher odds of adverse events. Bevacizumab seemed to be playing a dominant role, while corticosteroid seemed to be an negative factor in combination therapy.